SamuelSanchez RiveraMD

Dermatology • Caguas, PR

Auxiliary Professor-UPR School of Medicine Associate Professor-San Juan Bautista School of Medicine

Join to view full profile

Dr. Sanchez Rivera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanchez Rivera's full profile

Already have an account?

Office
200 Grand Boulevard Los Prados
Plaza Los Prados Suite Z-5
Caguas, PR 00727
Phone+1 787-746-3136

Summary

Samuel Sanchez Rivera, MD is a Dermatologist based in Caguas, PR. He completed his medical education at the University of Puerto Rico School of Medicine in 2002 as a Magna Cum Laude student, also earning several awards including the Mellado Parsons Award in 1998, the election as third year Alpha Omega Alpha Honor Society member in 1999 and the Betances Award in 2002. Dr. Sanchez completed his Transitional Year at the San Juan City Hospital and a Post Doctoral Fellow Research at the Neuro Aids program at the UPR Medical Sciences Campus where he also completed his residency at Dermatology Department, from 2004 to 2007. His clinical experience has a focus on general dermatology and clinical research and the academy. Dr. Sanchez has contributed to various publications in dermatological literature, with three notable ones published in Dermatologic Clinics, Pediatric Dermatology, and JAAD Case Reports. He has been involved in numerous clinical trials, primarily investigating treatments for moderate to severe plaque psoriasis and atopic dermatitis. Dr. Sanchez also is a leader on his medical field serving as President of the Puerto Rico in two occasions and occupying other positions on the Board of directors.

Education & Training

University of Puerto RicoResidency, Dermatology, 2004 - 2007
University of Puerto Rico School of MedicinePost-Doctoral Fellowship, 2003 - 2004
San Juan City HospitalInternship, Transitional Year, 2002 - 2003
University of Puerto Rico School of MedicineClass of 2002

Certifications & Licensure

PR State Medical License 2019 - 2025
American Board of Dermatology Dermatology
NIHPrinciples of Clinical Research

Awards, Honors, & Recognition

Magna Cum Laude University of Puerto Rico School of Medicine, 2002
Betances Award University of Puerto Rico School of Medicine, 2002
Alpha Omega Alpha Universitiy of Puerto Rico School of Medicine, 1999

Clinical Trials

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients Start of enrollment: 2003 Sep 01
Terminated
Phase 2
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris Start of enrollment: 2015 Nov 01
Completed
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Start of enrollment: 2018 Mar 14
Recruiting
Phase 3
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Start of enrollment: 2018 Jun 26
Completed
Phase 3
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Start of enrollment: 2018 Sep 03
Terminated
Phase 3
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27
Terminated
Phase 3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Aug 09
Enrolling by invitation
Phase 3
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Nov 09
Completed
Phase 4
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Dec 27
Completed
Phase 2
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2019 May 13
Completed
Phase 3
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Start of enrollment: 2023 Dec 19
Enrolling by invitation
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Start of enrollment: 2023 Jun 21
Recruiting
Phase 3
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement Start of enrollment: 2021 Feb 26
Completed
Phase 3
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2022 Nov 28
Active, not recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata Start of enrollment: 2023 Oct 11
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab Start of enrollment: 2024 Jun 12
Recruiting
Phase 3
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting Start of enrollment: 2023 Jan 31
Active, not recruiting
Phase 4
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) Start of enrollment: 2023 Feb 21
Active, not recruiting
Phase 3
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD Start of enrollment: 2022 Jul 07
Recruiting
Phase 3
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Start of enrollment: 2020 Nov 25
Recruiting
Phase 3
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Start of enrollment: 2020 Jun 15
Recruiting
Phase 3
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Start of enrollment: 2020 Jun 30
Recruiting
Phase 3
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Start of enrollment: 2021 Nov 04
Completed
Phase 2
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis Start of enrollment: 2018 Nov 29
Completed
Phase 1
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Start of enrollment: 2016 Jun 22
Completed
Phase 3
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine Start of enrollment: 2023 Jun 05
Enrolling by invitation
Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Start of enrollment: 2023 May 01
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Chronic spontaneous urticaria associated with colon adenocarcinoma: A paraneoplastic manifestation? A case report and review of literature
Marely Santiago-Vázquez, Julián Barrera-Llaurador, Osward Y. Carrasquillo, Samuel Sanchez
JAAD Case Reports. 2019-01-01
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplanta...
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Brad Glick, Mar Llamas-Velasco
Journal of the American Academy of Dermatology. 2024-08-30
24 citations
Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox.
Jorge R Toro, Samuel Sanchez, George W. Turiansky, Andrew Blauvelt
Dermatologic Clinics. 2003-04-01

Professional Memberships

American Academy of Dermatology - AAD
Member
Sociedad Dermatológica De Puerto Rico
Member

Other Languages

Spanish

Industry Relationships

Speaker, Pfizer2020 - Present